Index,A_P,A_I,A_C,A_O,A_S,A_Decision,A_Reason
0,patients with advanced biliary tract cancer,pembrolizumab plus gemcitabine and cisplatin,placebo plus gemcitabine and cisplatin,overall survival,"randomized, double-blind, placebo-controlled, phase 3 trial",False,"population is biliary tract cancer, not hepatocellular carcinoma"
1,patients with unresectable hepatocellular carcinoma,lenvatinib,sorafenib,overall survival,"open-label, phase 3, non-inferiority trial",False,intervention is not an immune checkpoint inhibitor
2,patients with unresectable hepatocellular carcinoma,atezolizumab plus bevacizumab,sorafenib,overall survival and progression-free survival,"global, open-label, phase 3 trial",True,matches all PICOS criteria
3,patients with unresectable hepatocellular carcinoma,atezolizumab plus bevacizumab,sorafenib,overall survival and progression-free survival,"open-label, phase III study",True,matches all PICOS criteria
4,patients with unresectable hepatocellular carcinoma,camrelizumab plus rivoceranib,sorafenib,progression-free survival and overall survival,"randomised, open-label, phase 3 trial",True,matches all PICOS criteria
5,patients with unresectable hepatocellular carcinoma,tremelimumab plus durvalumab,sorafenib,overall survival,"global, open-label, phase 3 trial",True,matches all PICOS criteria
6,patients with unresectable hepatocellular carcinoma,tremelimumab plus durvalumab,sorafenib,overall survival,randomized phase 3 trial,True,matches all PICOS criteria
7,"patients with HER2-negative, unresectable gastric or gastro-oesophageal junction cancer",nivolumab plus oxaliplatin-based chemotherapy,placebo plus oxaliplatin-based chemotherapy,progression-free survival and overall survival,"randomised, double-blind, placebo-controlled, phase 2-3 trial",False,"population is gastric or gastro-oesophageal junction cancer, not hepatocellular carcinoma"
8,patients with advanced hepatocellular carcinoma,lenvatinib plus transarterial chemoembolization,lenvatinib monotherapy,overall survival,"multicenter, randomized, open-label, phase III trial",False,intervention is not an immune checkpoint inhibitor
9,patients with unresectable hepatocellular carcinoma,lenvatinib plus pembrolizumab,lenvatinib plus placebo,overall survival and progression-free survival,"randomised, double-blind, phase 3 study",True,matches all PICOS criteria
10,patients with advanced hepatocellular carcinoma previously treated with sorafenib,cabozantinib,placebo,"overall survival, progression-free survival, objective response rate","randomized, double-blind, phase 3 trial",False,intervention is not an immune checkpoint inhibitor
11,"patients with advanced hepatocellular carcinoma, no previous systemic therapy",nivolumab,sorafenib,overall survival,"randomized, open-label, phase 3 trial",True,matches PICOS criteria
12,patients with hepatocellular carcinoma who progressed on sorafenib,regorafenib,placebo,overall survival,"randomized, double-blind, phase 3 trial",False,intervention is not an immune checkpoint inhibitor
13,"patients with unresectable HBV-associated hepatocellular carcinoma, no previous systemic treatment",sintilimab plus IBI305,sorafenib,"overall survival, progression-free survival","randomized, open-label, phase 2-3 trial",True,matches PICOS criteria
14,patients with advanced hepatocellular carcinoma previously treated with sorafenib,nivolumab plus ipilimumab,not specified,"objective response rate, safety","randomized, open-label, phase 1/2 trial",True,matches PICOS criteria
15,"patients with unresectable hepatocellular carcinoma, no previous systemic therapy",tislelizumab,sorafenib,"overall survival, objective response rate, progression-free survival","randomized, open-label, phase 3 trial",True,matches PICOS criteria
16,hepatocellular carcinoma patients with microvascular invasion,FOLFOX-HAIC,routine follow-up,"disease-free survival, overall survival","randomized, open-label, multicenter trial",False,intervention is not an immune checkpoint inhibitor
17,patients with unresectable hepatocellular carcinoma,FOLFOX-HAIC,TACE,"overall survival, progression-free survival","randomized, multicenter, open-label trial",False,intervention is not an immune checkpoint inhibitor
18,patients with unresectable hepatocellular carcinoma,lenvatinib,sorafenib,"overall survival, progression-free survival, objective response rate","randomized, non-inferiority, phase 3 trial",False,intervention is not an immune checkpoint inhibitor
19,patients with hepatocellular carcinoma beyond Milan criteria,liver transplantation,non-transplantation therapies,"tumor event-free survival, overall survival","randomized, controlled trial",False,intervention is not an immune checkpoint inhibitor
20,patients with advanced hepatocellular carcinoma,atezolizumab + bevacizumab,tyrosine kinase inhibitors or other therapies,recommended care options,systematic review of phase III randomized controlled trials,False,outcome does not match survival or response rate
21,patients with unresectable hepatocellular carcinoma,atezolizumab plus bevacizumab,lenvatinib,overall survival,retrospective multi-centre study,False,study design is not a randomized controlled trial
22,patients with advanced hepatocellular carcinoma,cabozantinib plus atezolizumab,sorafenib or single-agent cabozantinib,progression-free survival and overall survival,"randomized, phase 3 trial",True,matches all PICOS criteria
23,patients with hepatocellular carcinoma and portal vein invasion,sorafenib plus hepatic arterial infusion chemotherapy,sorafenib alone,overall survival,"randomized, open-label clinical trial",False,intervention does not involve immune checkpoint inhibitors
24,patients with advanced hepatocellular carcinoma and high α-fetoprotein,ramucirumab,placebo,overall survival,"randomized, double-blind, phase 3 trial",False,intervention is not an immune checkpoint inhibitor
25,patients with advanced intrahepatic cholangiocarcinoma,"toripalimab, lenvatinib, and gemcitabine plus oxaliplatin",not specified,objective response rate,not specified,False,population and intervention do not match PICOS criteria
26,patients with unresectable or metastatic hepatocellular carcinoma,donafenib,sorafenib,overall survival,"randomized, phase II-III trial",False,intervention is not an immune checkpoint inhibitor
27,patients with advanced hepatocellular carcinoma previously treated with sorafenib,pembrolizumab,placebo,overall survival and progression-free survival,"randomized, double-blind, phase III study",True,matches all PICOS criteria
28,patients with intermediate-stage hepatocellular carcinoma,lenvatinib plus pembrolizumab plus TACE,placebos plus TACE,overall survival and progression-free survival,"prospective, double-blind randomized phase 3 study",True,matches all PICOS criteria
29,patients with unresectable hepatocellular carcinoma,TACE plus sorafenib,TACE alone,progression-free survival and overall survival,randomized trial,False,intervention does not involve immune checkpoint inhibitors
30,patients with unresectable hepatocellular carcinoma,tremelimumab and durvalumab as monotherapies and in combination,different dosing regimens of tremelimumab and durvalumab,objective response rate and overall survival,randomized controlled trial,True,"matches PICOS criteria: population, intervention, comparison, outcome, and study design"
31,patients from Asia with previously treated advanced hepatocellular carcinoma,pembrolizumab,placebo,"overall survival, progression-free survival, and objective response rate",randomized controlled trial,True,"matches PICOS criteria: population, intervention, comparison, outcome, and study design"
32,patients with intermediate-stage hepatocellular carcinoma,yttrium-90 transarterial radioembolization,doxorubicin drug-eluting bead transarterial chemoembolization,time to overall tumor progression and overall survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
33,patients with hepatocellular carcinoma,anti-PD-1 immunotherapy,not specified,early detection and efficacy assessment,not specified,False,no comparison or randomized controlled trial design
34,patients with advanced hepatocellular carcinoma and major portal vein tumor thrombosis,sorafenib plus hepatic arterial infusion chemotherapy,sorafenib alone,overall survival and progression-free survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
35,patients with unresectable hepatocellular carcinoma,lenvatinib vs. sorafenib,lenvatinib vs. sorafenib,overall survival and objective response,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
36,patients with hepatocellular carcinoma after surgical resection or local ablation,sorafenib,placebo,recurrence-free survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
37,patients with hepatocellular carcinoma receiving transcatheter arterial chemoembolization,Fuzheng Jiedu Xiaoji formulation combined with standard treatment,standard treatment alone,overall survival and progression-free survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
38,patients with hepatocellular carcinoma of BCLC stages A or B,yttrium-90 radioembolization,conventional transarterial chemoembolization,time to progression and survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
39,patients with pretreated advanced hepatocellular carcinoma,apatinib,placebo,overall survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
40,patients with advanced hepatocellular carcinoma,HAIC-FO,sorafenib,overall survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
41,patients with hepatocellular carcinoma and microvascular invasion,sintilimab (PD-1 inhibitor),active surveillance,recurrence-free survival,randomized controlled trial,True,matches all PICOS criteria
42,patients with unresectable hepatocellular carcinoma,atezolizumab + bevacizumab,sorafenib,"objective response rate, depth and duration of response",randomized controlled trial,True,matches all PICOS criteria
43,patients with hepatocellular carcinoma,POSTN gene knockdown,not specified,tumor formation and stemness factors,not specified,False,intervention is not immune checkpoint inhibitors
44,patients with hepatocellular carcinoma and macroscopic vascular invasion,TACE plus RT,sorafenib,"progression-free survival, overall survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
45,patients with advanced hepatocellular carcinoma,atezolizumab + bevacizumab,sorafenib,patient-reported outcomes,randomized controlled trial,True,matches all PICOS criteria
46,patients with advanced hepatocellular carcinoma,selective internal radiotherapy,sorafenib,overall survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
47,patients with hepatocellular carcinoma,sorafenib,placebo,recurrence-free survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
48,patients with recurrent intermediate-stage hepatocellular carcinoma,sorafenib plus TACE,TACE alone,overall survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
49,patients with advanced hepatocellular carcinoma,cabozantinib plus atezolizumab,sorafenib,"overall survival, progression-free survival",randomized controlled trial,True,matches all PICOS criteria
50,patients with advanced hepatocellular carcinoma,nivolumab plus ipilimumab,different dosing regimens of nivolumab and ipilimumab,"objective response rate, duration of response, overall survival",randomized controlled trial,True,"matches PICOS criteria: population, intervention, comparison, outcome, and study design align"
51,patients with hepatocellular carcinoma,proton beam radiotherapy,transarterial chemoembolization,"overall survival, progression-free survival, local control",randomized controlled trial,False,intervention does not involve immune checkpoint inhibitors
52,HBV-related hepatocellular carcinoma patients,adjuvant transarterial chemoembolization,no adjuvant treatment,"recurrence-free survival, overall survival",randomized phase 3 trial,False,intervention does not involve immune checkpoint inhibitors
53,patients with unresectable hepatocellular carcinoma,STRIDE regimen (tremelimumab plus durvalumab),sorafenib,"patient-reported outcomes, time to deterioration",randomized controlled trial,True,"matches PICOS criteria: population, intervention, comparison, outcome, and study design align"
54,patients with unresectable hepatocellular carcinoma,tremelimumab plus durvalumab,sorafenib,overall survival,randomized controlled trial,True,"matches PICOS criteria: population, intervention, comparison, outcome, and study design align"
55,patients with hepatocellular carcinoma and portal vein tumor thrombus,sorafenib plus transarterial chemoembolization,sorafenib alone,"recurrence-free survival, overall survival",randomized phase 3 trial,False,intervention does not involve immune checkpoint inhibitors
56,patients with unresectable hepatocellular carcinoma,lenvatinib,sorafenib,health-related quality of life,randomized phase 3 trial,False,intervention does not involve immune checkpoint inhibitors
57,patients with hepatocellular carcinoma,radiation therapy,not specified,"local control, progression-free survival",not specified,False,intervention does not involve immune checkpoint inhibitors
58,patients with hepatocellular carcinoma,TACE-DEB,stereotactic body radiation therapy,"time to progression, local control, overall survival",randomized trial,False,intervention does not involve immune checkpoint inhibitors
59,patients with advanced hepatocellular carcinoma,nivolumab plus cabozantinib with or without ipilimumab,not specified,"objective response rate, progression-free survival, overall survival",phase I/II study,True,"matches PICOS criteria: population, intervention, outcome, and study design align, though comparison is not specified"
60,patients with hepatocellular carcinoma and Vp4 PVTT,irradiation stent placement with 125 I plus TACE,sorafenib plus TACE,"overall survival, hepatic function, time to symptomatic progression, disease control rate",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
61,massive hepatocellular carcinoma patients,camrelizumab plus TACE,TACE alone,"clinical efficacy, adverse events, liver function, biomarker levels",randomized controlled trial,True,matches PICOS criteria: camrelizumab is an immune checkpoint inhibitor
62,patients with unresectable hepatocellular carcinoma,Tislelizumab,Sorafenib,"cost-effectiveness, quality-adjusted life-years",randomized clinical trial,True,matches PICOS criteria: Tislelizumab is an immune checkpoint inhibitor
63,patients with nonresected hepatocellular carcinoma,lenvatinib,sorafenib,"cost-effectiveness, quality-adjusted life-years",randomized clinical trial,False,intervention is not immune checkpoint inhibitors
64,intermediate stage hepatocellular carcinoma patients,TACE plus sorafenib,TACE alone,"time-to-complete response, time-to-TACE progression, progression-free survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
65,advanced hepatocellular carcinoma patients,TACE followed by HAIC with or without oral S-1,TACE followed by HAIC,"progression-free survival, overall survival, objective response rate",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
66,hepatocellular carcinoma patients undergoing TACE,"prophylactic antibiotics (ceftriaxone, levofloxacin, ciprofloxacin)",intravenous vs oral administration,"infection prevention, safety",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
67,hepatocellular carcinoma patients exceeding Milan criteria,neoadjuvant pembrolizumab plus lenvatinib,control group (no neoadjuvant therapy),"recurrence-free survival, tumor necrosis, safety",randomized controlled trial,True,matches PICOS criteria: pembrolizumab is an immune checkpoint inhibitor
68,hepatocellular carcinoma patients,not specified,not specified,"prognosis prediction, survival time",not specified,False,intervention and study design not specified
69,inoperable stage III hepatocellular carcinoma patients,sunitinib plus TACE,sorafenib plus TACE,"overall survival, progression-free survival, response rate",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
70,patients with intermediate stage HCC,DEB-TACE plus sorafenib,placebo plus DEB-TACE,"time-to-tumor progression, overall survival, response rate",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
72,patients with advanced HCC previously treated with sorafenib,pembrolizumab,placebo,"overall survival, quality-adjusted life-years",randomized controlled trial,True,matches all PICOS criteria
73,patients with HCC not suitable for surgical resection,sunitinib plus doxorubicin-TACE,placebo plus doxorubicin-TACE,"progression-free survival, overall survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
74,HCC patients with portal vein tumor thrombus,DEB-TACE,conventional TACE,"progression-free survival, overall survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
75,patients with asymptomatic synchronous unresectable CRLMs,pre-PTR chemotherapy,upfront PTR,"progression-free survival, overall survival",randomized controlled trial,False,population is not HCC patients
76,HCC patients who underwent hepatectomy,postoperative adjuvant TACE,no postoperative adjuvant TACE,"disease-free survival, overall survival",retrospective analysis,False,study design is not randomized controlled trial
77,HCC patients after narrow-margin hepatectomy,radiotherapy,TACE,"overall survival, progression-free survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
78,HCC patients with high recurrence risk,PD-1 inhibitors,no PD-1 inhibitors,"relapse-free survival, overall survival",single-arm phase 2 trial,False,study design is not randomized controlled trial
79,HR+/Her2- locally advanced breast cancer patients,DEB-TACE combined with systemic chemotherapy,systemic chemotherapy alone,"overall response rate, pathological complete response",randomized controlled trial,False,population is not HCC patients
71,not applicable,not applicable,not applicable,not applicable,not applicable,False,Abstract too short or empty
80,patients with locally advanced HCC,yttrium-90 resin microspheres RE,sorafenib 800 mg/d,overall survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
81,patients with HCC and PVTT,TACE plus lenvatinib,TACE plus sorafenib,"time-to-progression, objective response rate",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
82,patients with Child-Pugh class B/C HCC,sorafenib,best supportive care,"progression-free survival, overall survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
83,patients with unresectable HCC,TACE with dicycloplatin,TACE with epirubicin,"objective response rate, disease control rate",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
84,"patients with advanced solid tumors, including HCC",SAR439459 ± cemiplimab,not specified,"antitumor activity, safety",phase I/Ib study,False,study design is not randomized controlled trial
85,patients with HBV-related HCC and PHT,partial hepatectomy,interventional treatment (ablation ± TACE),"overall survival, recurrence-free survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
86,patients with advanced HCC and ALBI grade 1/2,cabozantinib,placebo,"overall survival, progression-free survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
87,patients with renal cell carcinoma,DEE transarterial chemoembolization,transarterial embolization,"necrosis rate, safety",randomized controlled trial,False,population is not HCC patients
88,patients with unresectable HCC,lenvatinib,sorafenib,"overall survival, progression-free survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
89,patients with HCC undergoing TACE,TACE via TRA or TFA,not specified,radiation dose received by operator,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
90,patients with advanced hepatocellular carcinoma,doxorubicin plus sorafenib,sorafenib alone,overall survival and progression-free survival,randomized phase III trial,False,intervention is not immune checkpoint inhibitors
91,patients with advanced hepatocellular carcinoma,sorafenib combined with cTACE,sorafenib alone,"overall survival, progression-free survival, and tumor response rate",randomized phase III trial,False,intervention is not immune checkpoint inhibitors
92,patients with advanced hepatocellular carcinoma,SIRT plus sorafenib,sorafenib alone,overall survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
93,patients with hepatocellular carcinoma and portal vein tumor thrombus,radiotherapy prior to TACE,TACE followed by radiotherapy,overall survival and progression-free survival,randomized controlled study,False,intervention is not immune checkpoint inhibitors
94,patients with hepatocellular carcinoma,sorafenib or SIRT plus sorafenib,not specified,overall survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
95,patients with unresectable hepatocellular carcinoma,DEB-TACE combined with apatinib,DEB-TACE monotherapy,progression-free survival and overall survival,randomized phase III trial,False,intervention is not immune checkpoint inhibitors
96,patients with unresectable hepatocellular carcinoma,DEB-TACE with CalliSpheres microspheres,conventional TACE,overall survival and progression-free survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
97,patients with advanced hepatocellular carcinoma,SIRT plus sorafenib,sorafenib alone,overall survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
98,patients with unresectable hepatocellular carcinoma,raltitrexed plus OXA-based TACE,fluorouracil or doxorubicin plus OXA-based TACE,overall survival and progression-free survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
99,patients with unresectable hepatocellular carcinoma,camrelizumab plus rivoceranib,sorafenib,overall survival and progression-free survival,randomized phase III trial,True,matches all PICOS criteria
100,patients with hepatocellular carcinoma,DEB-TACE,not specified,risk of acute liver function deterioration,retrospective study,False,Intervention and outcome do not match PICOS criteria.
101,patients with advanced hepatocellular carcinoma,sorafenib and selective internal radiation therapy,not specified,overall survival and liver decompensation,post hoc analysis,False,Intervention and study design do not match PICOS criteria.
102,patients with advanced hepatocellular carcinoma,cabozantinib,placebo,overall survival and progression-free survival,randomized controlled trial,False,Intervention is not an immune checkpoint inhibitor.
103,patients with HBV-related unresectable hepatocellular carcinoma,lenvatinib,sorafenib,"overall survival, progression-free survival, and tumor response",retrospective study,False,Intervention and study design do not match PICOS criteria.
104,patients with unresectable hepatocellular carcinoma,sorafenib,placebo,overall survival,pooled exploratory analysis,False,Intervention is not an immune checkpoint inhibitor.
105,patients with unresectable hepatocellular carcinoma,lenvatinib,sorafenib,overall survival,post hoc analysis,False,Intervention and study design do not match PICOS criteria.
106,patients with hepatocellular carcinoma,sorafenib,placebo,RFA coagulation zone size and thermal parameters,randomized controlled trial,False,Intervention and outcome do not match PICOS criteria.
107,patients with unresectable hepatocellular carcinoma,hepatic arterial infusion chemotherapy,not specified,therapeutic response and progression-free survival,retrospective study,False,Intervention and study design do not match PICOS criteria.
108,patients with unresectable hepatocellular carcinoma,TACE with miriplatin,TACE with epirubicin,overall survival,randomized controlled trial,False,Intervention is not an immune checkpoint inhibitor.
109,patients with advanced hepatocellular carcinoma,SIRT + sorafenib,sorafenib alone,treatment response prediction,randomized controlled trial,False,Intervention is not an immune checkpoint inhibitor.
110,patients with hepatocellular carcinoma,Stereotactic Body Radiotherapy (SBRT),standard TAE/TACE,"1-year local control, progression-free survival, overall survival",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
111,patients with high-risk recurrence factors after curative resection of HCC,Cidan Capsule combined with TACE,TACE without Cidan Capsule,"disease-free survival, tumor recurrence rate, overall survival",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
112,patients with advanced hepatocellular carcinoma,SIRT+sorafenib,sorafenib alone,"survival benefit, liver function",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
113,patients with advanced hepatocellular carcinoma,sorafenib-pravastatin combination,sorafenib alone,"overall survival, progression-free survival",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
114,patients with advanced hepatocellular carcinoma,ramucirumab,placebo,"overall survival, post-progression survival",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
115,patients with hepatocellular carcinoma,repeated cTACE,not specified,overall survival,not specified,False,Intervention is not immune checkpoint inhibitors (ICIs)
116,patients with hepatocellular carcinoma,sorafenib + vitamin K2,sorafenib only,"progression-free survival, overall survival",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
117,patients with medium-advanced hepatocellular carcinoma,TACE with bleomycin,TACE without bleomycin,"overall survival, progression-free survival",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
118,patients with hepatocellular carcinoma,TACE with low-dose doxorubicin,TACE with standard-dose doxorubicin,"overall survival, post-embolisation syndrome",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
119,advanced HCC patients with variceal bleeding,TIPS,endoscopic + β-blocker therapy,"rebleeding, overall survival",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
120,patients with unresectable and advanced HCC,TACE combined with celecoxib and lanreotide,TACE alone,"overall survival, disease control rate",randomized controlled trial,False,intervention does not involve immune checkpoint inhibitors
121,patients with HCC admitted for TACE,intravenous N-acetylcysteine,placebo,incidence of post-embolization syndrome,randomized controlled trial,False,intervention does not involve immune checkpoint inhibitors
122,patients with primary liver cancer,Fuzheng Jiedu Xiaoji formula plus TACE,TACE alone,"disease control rate, liver biochemistry",randomized controlled trial,False,intervention does not involve immune checkpoint inhibitors
123,patients with HCC >3-<5 cm,combined therapy with cTACE and microwave ablation,TACE alone or microwave ablation alone,"complete response, recurrence rate, overall survival",randomized controlled trial,False,intervention does not involve immune checkpoint inhibitors
124,patients with unresectable HCC,TACE with cisplatin,TACE with epirubicin,"overall survival, tumor response",randomized controlled trial,False,intervention does not involve immune checkpoint inhibitors
125,patients with unresectable HCC,selective internal radiation therapy,sorafenib,overall survival,post-hoc analysis of randomized trial,False,intervention does not involve immune checkpoint inhibitors
126,patients with gastroesophageal junction cancer and hepatic metastasis,transarterial infusion chemotherapy plus microsphere embolization,transarterial infusion chemotherapy alone,"median survival time, survival rates",randomized controlled trial,False,population and intervention do not match target criteria
127,patients with primary hepatic carcinoma,lobaplatin in TACE,pirarubicin hydrochloride in TACE,"survival time, therapeutic response",randomized controlled trial,False,intervention does not involve immune checkpoint inhibitors
128,HCC patients resistant to TACE with doxorubicin,TACE with bleomycin,TACE with doxorubicin,"progression-free survival, overall survival",randomized controlled trial,False,intervention does not involve immune checkpoint inhibitors
129,"patients with unresectable, liver-confined HCC",TACE with sorafenib,TACE with placebo,progression-free survival,randomized controlled trial,False,intervention does not involve immune checkpoint inhibitors
130,patients with CRLM,TACE with DSM or lipiodol,TACE with lipiodol vs DSM,tumor response and survival rate,randomized controlled trial,False,"Population is CRLM, not hepatocellular carcinoma"
131,patients with HCC,prophylactic HAIC,HAIC vs no HAIC,"recurrence-free survival, disease-free survival, overall survival",randomized controlled trial,False,"Intervention is HAIC, not immune checkpoint inhibitors"
132,patients with HCC and tumor portal invasion,percutaneous ablation,ablation vs sorafenib or TARE,overall survival and progression-free survival,retrospective study,False,"Study design is retrospective, not randomized controlled trial"
133,patients with HCC,TRA vs TFA for TACE,TRA vs TFA,patient satisfaction and procedural variables,randomized controlled trial,False,"Intervention is TRA/TFA, not immune checkpoint inhibitors"
134,patients with HCC and PVTT,"LR, TACE, or sorafenib",LR vs TACE vs sorafenib,overall survival,randomized controlled trial,False,"Intervention is LR/TACE/sorafenib, not immune checkpoint inhibitors"
135,HBV-related HCC patients,lamivudine with TACE,lamivudine vs control,time to progression and overall survival,randomized controlled trial,False,"Intervention is lamivudine, not immune checkpoint inhibitors"
136,patients with aHCC,sorafenib-GEMOX vs sorafenib,sorafenib-GEMOX vs sorafenib,progression-free survival and overall survival,randomized controlled trial,False,"Intervention is sorafenib-GEMOX, not immune checkpoint inhibitors"
137,patients with unresectable HCC,TEA vs TACE,TEA vs TACE,"overall survival, time to progression, tumor response",randomized controlled trial,False,"Intervention is TEA/TACE, not immune checkpoint inhibitors"
138,patients with HCC and AFP ≥400 ng/mL,ramucirumab,ramucirumab vs placebo,"overall survival, progression-free survival",post-hoc analysis of phase III trials,False,"Intervention is ramucirumab, not immune checkpoint inhibitors"
139,HBV-related HCC patients,TACE,not specified,severe abdominal pain post-TACE,randomized controlled trial,False,"Intervention is TACE, not immune checkpoint inhibitors"
140,patients with advanced HCC,sorafenib plus hepatic arterial infusion chemotherapy with cisplatin,sorafenib alone,"overall survival, time to progression, response rate",randomized controlled trial,False,intervention does not involve immune checkpoint inhibitors
141,patients with stage B or C liver cancer,early percutaneous transhepatic varices embolization,control group without PTVE,"hemorrhage rates, liver function, tumor control",randomized controlled trial,False,intervention does not involve immune checkpoint inhibitors
142,patients with medium-sized HCC,sorafenib combined with radiofrequency ablation,radiofrequency ablation alone,"recurrence rates, time to progression",randomized controlled trial,False,intervention does not involve immune checkpoint inhibitors
143,patients with advanced HCC,linifanib,sorafenib,"overall survival, time to progression, response rate",randomized controlled trial,False,intervention does not involve immune checkpoint inhibitors
144,patients with locally advanced or inoperable HCC,transarterial radioembolisation,sorafenib,health-related quality of life,randomized controlled trial,False,intervention does not involve immune checkpoint inhibitors
145,patients with HCC,not specified,not specified,quality of life impact of adverse events,randomized controlled trial,False,intervention not specified and does not involve immune checkpoint inhibitors
146,patients with unresectable HCC undergoing TACE,"celecoxib, parecoxib, or oxycodone",comparison among the three analgesics,"pain control, adverse events",randomized controlled trial,False,intervention does not involve immune checkpoint inhibitors
147,patients with sorafenib-refractory advanced HCC,S-1,placebo,overall survival,randomized controlled trial,False,intervention does not involve immune checkpoint inhibitors
148,patients with advanced HCC,sorafenib plus metformin,sorafenib alone,"treatment response, time to progression, overall survival",randomized controlled trial,False,intervention does not involve immune checkpoint inhibitors
149,patients with HCC receiving sorafenib,not specified,not specified,"overall survival, objective response",randomized controlled trial,False,intervention not specified and does not involve immune checkpoint inhibitors
150,patients with unresectable hepatocellular carcinoma,drug-eluting microspheres TACE (DEM-TACE),conventional TACE (c-TACE),12- and 24-month survival rates,randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
151,patients with primary hepatic carcinoma,TACE with gelatin sponge particles plus Huaier granule,TACE with gelatin sponge particles plus lobaplatin,overall survival and tumor response rates,randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
152,patients with hepatocellular carcinoma requiring TACE,TACE with low-molecular-weight heparins (LMWHs),TACE without LMWHs,incidence of portal vein thrombosis,randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
153,patients with liver cancer after TACE,individualized nutritional intervention,routine dietary intervention,"nutritional status, liver function, and complications",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
154,patients with resectable multiple hepatocellular carcinoma,partial hepatectomy,transcatheter arterial chemoembolization (TACE),overall survival,randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
155,patients with unresectable hepatocellular carcinoma,selective internal radiation therapy (SIRT),transarterial chemoembolization (TACE),"safety, health-related quality of life, and tumor response",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
156,patients with large or huge hepatocellular carcinoma,CalliSpheres beads loaded with arsenic trioxide (CBATO-TACE),conventional TACE (cTACE),progression-free survival and overall survival,randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
157,patients with unresectable hepatocellular carcinoma,image-guided high-dose-rate brachytherapy (iBT),conventional transarterial embolization (cTACE),time to untreatable progression and overall survival,randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
158,patients with advanced hepatocellular carcinoma,regorafenib,placebo,life-years and quality-adjusted life-years (QALYs),randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
159,patients with unresectable hepatocellular carcinoma,atezolizumab and bevacizumab,sorafenib,quality-adjusted life-years (QALYs) and cost-effectiveness,randomized controlled trial,True,Intervention includes immune checkpoint inhibitors (ICIs)
160,patients with hepatocellular carcinoma and Child-Pugh B cirrhosis,"sorafenib, pravastatin, or combination",best supportive care,"time to progression, overall survival",randomized controlled trial,False,intervention does not include immune checkpoint inhibitors
161,patients with advanced hepatocellular carcinoma,urea-based cream,best supportive care or moisturizing cream,incidence of hand-foot skin reaction,randomized double-blind experimental study,False,intervention does not include immune checkpoint inhibitors
162,patients with advanced hepatocellular carcinoma,trebananib plus sorafenib,historical sorafenib control,"progression-free survival, overall survival",nonrandomized cohorts,False,intervention does not include immune checkpoint inhibitors
163,patients with hepatocellular carcinoma,gadobenate dimeglumine-enhanced MR,not specified,tumor response after TACE,not specified,False,intervention does not include immune checkpoint inhibitors
164,patients with unresectable hepatocellular carcinoma,DEB-TACE with doxorubicin-loaded CalliSpheres,conventional TACE,"clinical response rate, overall survival, progression-free survival",randomized controlled trial,False,intervention does not include immune checkpoint inhibitors
165,cirrhotic hepatocellular carcinoma patients,L-carnitine,control group,liver function after TACE,not specified,False,intervention does not include immune checkpoint inhibitors
166,patients with hepatocellular carcinoma post-sorafenib,cabozantinib,placebo,"overall survival, progression-free survival",Phase III randomized controlled trial,False,intervention does not include immune checkpoint inhibitors
167,patients with unresectable hepatocellular carcinoma,HAIC combined with donafenib,HAIC alone,"progression-free survival, tumor markers",randomized controlled trial,False,intervention does not include immune checkpoint inhibitors
168,patients undergoing DEE-TACE for hepatocellular carcinoma,hepatic hilar and celiac plexus nerve blocks,standard intraprocedural local anesthetic,"pain, patient satisfaction, adverse events",prospective randomized trial,False,intervention does not include immune checkpoint inhibitors
169,patients with unresectable hepatocellular carcinoma,TACE followed by SBRT,TACE alone,"local control, progression-free survival, overall survival",randomized controlled trial,False,intervention does not include immune checkpoint inhibitors
170,patients with locally advanced and inoperable hepatocellular carcinoma,transarterial radioembolization (TARE),sorafenib,"cost-utility analysis, life-years, quality-adjusted life-years (QALYs)",economic evaluation using patient-level data from a randomized controlled trial,False,intervention is not immune checkpoint inhibitors (ICIs)
171,patients with HCC awaiting liver transplantation,sorafenib plus radioembolization (Y90),Y90 alone,"adverse events, dose reductions, peri-transplant complications, survival rates",randomized controlled trial,False,intervention is not immune checkpoint inhibitors (ICIs)
172,patients with primary liver cancer,TACE plus high intensity focused ultrasound (HIFU),TACE alone,"remission rate, AFP levels, liver function indicators, complications, recurrence rate",randomized controlled trial,False,intervention is not immune checkpoint inhibitors (ICIs)
173,patients with hepatocellular carcinoma undergoing TACE,preoperative interview and prospective nursing,routine nursing care,"heart rate, blood pressure, mood changes, pain, satisfaction, complications",randomized controlled trial,False,intervention is not immune checkpoint inhibitors (ICIs)
174,patients with advanced hepatocellular carcinoma previously treated with sorafenib,regorafenib,placebo,"overall survival, progression-free survival, response rate",randomized controlled trial,False,intervention is not immune checkpoint inhibitors (ICIs)
175,patients with hepatocellular carcinoma,embolization with doxorubicin-eluting microspheres,embolization with microspheres alone,"response rate, progression-free survival, overall survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors (ICIs)
176,patients with TACE-eligible hepatocellular carcinoma,brivanib,placebo,"overall survival, time to disease progression, time to extrahepatic spread or vascular invasion",randomized controlled trial,False,intervention is not immune checkpoint inhibitors (ICIs)
177,patients with hepatocellular carcinoma undergoing TACE,not specified,not specified,risk factors for liver abscess formation,retrospective review,False,study design is not a randomized controlled trial
178,patients with advanced hepatocellular carcinoma,enzalutamide,placebo,"overall survival, progression-free survival, safety",randomized controlled trial,False,intervention is not immune checkpoint inhibitors (ICIs)
179,patients with inoperable intermediate- or advanced-stage hepatocellular carcinoma,radioembolization with yttrium-90 followed by sorafenib,sorafenib only,"safety, adverse events, liver function, performance status",randomized controlled trial,False,intervention is not immune checkpoint inhibitors (ICIs)
180,Chinese patients with advanced hepatocellular carcinoma,donafenib,200 mg vs 300 mg bid groups,"safety, pharmacokinetics, and efficacy",phase 1b trial,False,"Intervention is not immune checkpoint inhibitors (ICIs), and comparison is not against placebo or non-ICI treatment."
181,patients with liver cancers undergoing TACE,transcutaneous electrical acustimulation (TEA),TEA vs sham-TEA,"GI symptoms, gastric slow waves, and autonomic functions",randomized controlled trial,False,"Population is not specific to hepatocellular carcinoma, and intervention is not ICIs."
182,Japanese patients with advanced HCC and AFP ≥400 ng/mL,ramucirumab,ramucirumab vs placebo,overall survival (OS) and progression-free survival (PFS),randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs).
183,second-line hepatocellular carcinoma (HCC) patients,tivantinib,tivantinib vs placebo,survival and biomarker analysis,randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs).
184,pediatric hepatoblastoma (HB) patients,HIFU combined with TACE,HIFU + TACE vs TACE alone,"survival rate, immune function, and side effects",randomized controlled trial,False,"Population is pediatric hepatoblastoma, not hepatocellular carcinoma, and intervention is not ICIs."
185,intermediate-stage hepatocellular carcinoma (HCC) patients,LIPDOX or DEBDOX,LIPDOX vs DEBDOX,"pharmacokinetics, safety, and antitumor effects","prospective, nonrandomized multicenter study",False,"Intervention is not ICIs, and study design is not randomized controlled trial."
186,intermediate-stage hepatocellular carcinoma (HCC) patients,dexamethasone,dexamethasone vs placebo,postembolization syndrome (PES),randomized controlled trial,False,"Intervention is not ICIs, and outcome is not survival or response rate."
187,hepatocellular carcinoma (HCC) patients,cabozantinib,cabozantinib vs placebo,objective response rate (ORR) and progression-free survival (PFS),phase 2 randomized discontinuation trial,False,Intervention is not immune checkpoint inhibitors (ICIs).
188,Taiwanese patients with advanced HCC and Child-Pugh A status,sorafenib,sorafenib vs not specified,overall survival (OS) and progression-free survival (PFS),phase IV study,False,"Intervention is not ICIs, and comparison is not specified."
189,intermediate and advanced hepatocellular carcinoma (HCC) patients,TACE combined with apatinib,TACE + apatinib vs TACE alone,progression-free survival (PFS) and adverse reactions,randomized controlled trial,False,"Intervention is not ICIs, and outcome is not survival or response rate."
190,patients with primary carcinoma of the liver,TACE with lobaplatin,TACE with cisplatin,efficacy and adverse events,randomized controlled trial,False,"Population is hepatocellular carcinoma, but intervention is not immune checkpoint inhibitors."
191,patients with advanced HCC,sorafenib,not specified,"overall survival, time to progression, response rate",retrospective study,False,"Intervention is not immune checkpoint inhibitors, and study design is not randomized controlled trial."
192,HCC patients beyond Milan criteria,surgical resection or TACE,not specified,survival prediction,observational study,False,"Intervention is not immune checkpoint inhibitors, and study design is not randomized controlled trial."
193,patients with advanced HCC and AFP ≥400 ng/mL,ramucirumab,placebo,time to deterioration in symptoms and quality of life,randomized controlled trial,False,Intervention is not immune checkpoint inhibitors.
194,patients with advanced HCC,sorafenib,not specified,overall survival and toxicity,prospective study,False,"Intervention is not immune checkpoint inhibitors, and study design is not randomized controlled trial."
195,HCC patients,sorafenib with or without erlotinib,placebo,overall survival and time to progression,randomized controlled trial,False,Intervention is not immune checkpoint inhibitors.
196,Asian-Pacific patients with advanced HCC,dovitinib,sorafenib,overall survival and time to progression,randomized phase 2 study,False,Intervention is not immune checkpoint inhibitors.
197,HCC patients on waiting list for liver transplantation,TACE plus sorafenib,TACE plus placebo,time to progression and tumor response,randomized controlled trial,False,Intervention is not immune checkpoint inhibitors.
198,patients with unresectable HCC,miriplatin/DDP-H combination therapy,miriplatin monotherapy,progression-free survival and disease control rate,randomized phase 2 study,False,Intervention is not immune checkpoint inhibitors.
199,patients with primary hepatocellular carcinoma,TACE,radiofrequency ablation,short-term curative effect and survival,randomized controlled trial,False,Intervention is not immune checkpoint inhibitors.
200,patients with advanced HCC,cisplatin/5-fluorouracil (CF-HAIC) vs. adriamycin added to CF-HAIC (ACF-HAIC),CF-HAIC vs. ACF-HAIC,"overall survival, treatment response, time to progression",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
201,patients with advanced HCC who failed prior systemic therapy,codrituzumab (anti-GPC3 antibody),codrituzumab vs. placebo,"progression-free survival, overall survival",randomized phase II trial,False,intervention is not immune checkpoint inhibitors
202,patients with advanced HCC and pulmonary metastasis,arsenic trioxide (As2O3) intravenous infusion,TACE + As2O3 vs. TACE alone,"overall survival, clinical efficacy",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
203,patients with HCC who failed prior sorafenib therapy,doxorubicin-loaded nanoparticles,doxorubicin-loaded nanoparticles vs. standard care,overall survival,randomized phase III trial,False,intervention is not immune checkpoint inhibitors
204,patients with HCC,dual-phase cone-beam CT-guided TACE,DP-CBCT-guided TACE vs. conventional DSA-guided TACE,"tumor detectability, embolization success rate",randomized study,False,intervention is not immune checkpoint inhibitors
205,patients with HCC on sorafenib,urea cream,urea cream vs. placebo cream,"hand-foot skin reaction incidence, quality of life",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
206,patients with biopsy-confirmed HCC,"TACE with single, double, or triple chemotherapeutic agents",single vs. double vs. triple drug TACE,"overall survival, time to progression, objective response rate",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
207,patients with early-intermediate stage HCC,TACE combined with sorafenib,TACE + sorafenib vs. TACE alone,overall survival,post hoc analysis of a randomized trial,False,intervention is not immune checkpoint inhibitors
208,patients with unresectable HCC and lung metastasis,arsenic trioxide transarterial chemoembolization and intravenous administration,arsenic trioxide TACE + IV vs. arsenic trioxide TACE alone,"overall survival, time to progression, disease control rate",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
209,cirrhotic patients with HCC and portal vein tumor thrombus,sorafenib plus RFA of HCC and PVTT,sorafenib + RFA vs. sorafenib alone,3-year survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
210,patients with advanced hepatocellular carcinoma,bevacizumab and erlotinib,sorafenib,"overall survival, event-free survival, response rate",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
211,HCC patients with solitary tumor and microvascular invasion,adjuvant TACE after hepatectomy,hepatectomy alone,"disease-free survival, overall survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
212,HCC patients undergoing TACE,dexamethasone regimen,placebo,complete response rate for adverse events,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
213,patients with hepatic cell carcinoma,TACE combined with RFA,TACE alone,"overall effect, serum markers",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
214,patients with advanced hepatocellular carcinoma,resminostat plus sorafenib,sorafenib monotherapy,"time-to-progression, overall survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
215,Child-Pugh A patients with advanced HCC,sorafenib plus mFOLFOX,not specified,"time-to-progression, overall survival",single-arm phase II study,False,"intervention is not immune checkpoint inhibitors, no comparison group"
216,"patients with advanced, unresectable HCC",sorafenib plus hepatic arterial infusion chemotherapy,sorafenib alone,overall survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
217,advanced HCC with portal vein tumor thrombosis,hepatic arterial infusion chemotherapy,sorafenib,"overall survival, time to progression",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
218,patients with advanced HCC,sequential HAIC with cisplatin followed by sorafenib,sorafenib alone,"one-year survival rate, overall survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
219,HCC patients within Milan criteria,TACE plus RFA,partial hepatectomy,"overall survival, recurrence-free survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
220,patients with unresectable HCC and incomplete response after initial TACE,stereotactic ablative radiotherapy (SABR),re-TACE,"1-year freedom-from-local-progression rate, overall survival, response rate",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
221,patients with nonresectable single-lesion HCC,radiofrequency or microwave ablation combined with TACE,TACE alone,"success rate, complications",not specified,False,intervention is not immune checkpoint inhibitors
222,patients with inoperable HCC,transarterial chemoembolization with stable or unstable emulsions,stable vs unstable emulsions,"overall survival, tumor response",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
223,patients with unresectable or metastatic HCC,sorafenib with or without everolimus,sorafenib alone vs sorafenib + everolimus,"progression-free survival, overall survival, response rate",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
224,patients with advanced HCC who failed sorafenib,everolimus,placebo,"overall survival, time to progression",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
225,HCC patients receiving preoperative TACE,TACE,not specified,"recurrence rate, disease-free survival",retrospective study,False,intervention is not immune checkpoint inhibitors
226,HCC patients with AFP ≥400 ng/ml who progressed on sorafenib,ramucirumab,placebo,"cost-effectiveness, quality-adjusted life years",Markov model analysis,False,intervention is not immune checkpoint inhibitors
227,patients with advanced HCC,TACE with ginsenoside Rg3,TACE alone,"overall survival, disease control rate",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
228,patients with advanced HCC,AEG35156 with sorafenib,sorafenib alone,"progression-free survival, overall survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
229,patients with locally advanced HCC,SIRT or sorafenib,SIRT vs sorafenib,"overall survival, tumor response",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
230,patients with intrahepatic cholangiocellular carcinoma,chemoembolization or radioembolization,chemoembolization vs. radioembolization,"progression-free survival, overall survival, time to progression",randomized controlled trial,False,"population is cholangiocellular carcinoma, not hepatocellular carcinoma"
231,patients with hepatocellular carcinoma,transarterial chemoembolization (TACE),TACE vs. proton beam radiation therapy,"progression-free survival, overall survival, local tumor control",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
232,patients with advanced hepatocellular carcinoma,ramucirumab,ramucirumab vs. placebo,"quality of life, performance status",randomized controlled trial,False,"outcome is quality of life, not survival or response rate"
233,patients with primary or secondary liver cancer,transarterial chemoembolization (TACE),old vs. new C-arm imaging platform,"radiation exposure, image quality",prospective trial,False,intervention and outcome do not match PICOS criteria
234,patients with advanced hepatocellular carcinoma,sorafenib and bevacizumab,sorafenib and bevacizumab vs. sorafenib alone,"time to progression, survival",phase I/II trial,False,intervention is not immune checkpoint inhibitors
235,patients with hepatocellular carcinoma,doxorubicin-eluting bead-transarterial chemoembolization (DEB TACE) and sorafenib,not specified,"tumor response, survival",single center study,False,intervention and study design do not match PICOS criteria
236,patients with advanced hepatocellular carcinoma,mapatumumab and sorafenib,mapatumumab and sorafenib vs. placebo and sorafenib,"time to progression, progression-free survival, overall survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
237,patients with hepatocellular carcinoma,Jian Pi Li Qi (JPLQ) decoction,JPLQ vs. placebo vs. no treatment,"quality of life, liver function",randomized controlled trial,False,intervention and outcome do not match PICOS criteria
238,patients with advanced hepatocellular carcinoma,tigatuzumab and sorafenib,tigatuzumab and sorafenib vs. sorafenib alone,"time to progression, overall survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
239,patients with inoperable hepatocellular carcinoma,parecoxib sodium,parecoxib sodium vs. placebo,"pain control, quality of life",randomized controlled trial,False,intervention and outcome do not match PICOS criteria
240,patients with advanced hepatocellular carcinoma,sorafenib plus erlotinib,sorafenib plus placebo,"overall survival, response rate",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
241,patients with malignant liver lesions,4D-CTA guided TACE,traditional TACE,"contrast material, radiation exposure, diagnostic confidence",retrospective study,False,"population, intervention, and outcomes do not match PICOS"
242,patients with unresectable hepatocellular carcinoma,SIRT,DEB-TACE,"progression-free survival, overall survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
243,patients with hepatocellular carcinoma,low-dose X-ray system,reference X-ray system,"radiation dose, image quality",randomized controlled trial,False,intervention and outcomes do not match PICOS
244,patients with primary liver cancer,wrist-ankle acupuncture,oral morphine sulphate,"pain relief, adverse reactions",randomized controlled trial,False,"population, intervention, and outcomes do not match PICOS"
245,patients with advanced HBV-related hepatocellular carcinoma,tiopronin,no tiopronin,"liver function, treatment efficacy",prospective study,False,intervention and outcomes do not match PICOS
246,primary hepatocellular carcinoma patients,LRT combined with arsenic trioxide,LRT alone,"survival time, therapeutic response",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
247,patients with advanced hepatocellular carcinoma,nintedanib or sorafenib,not specified,overall survival,phase II clinical trials,False,intervention and study design do not match PICOS
248,patients with MET-high hepatocellular carcinoma,tivantinib,placebo,overall survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
249,patients with unresectable hepatocellular carcinoma,lenvatinib,sorafenib,overall survival,phase III trial,False,intervention is not immune checkpoint inhibitors
250,patients with hepatocellular carcinoma,transradial access in c-TACE,transfemoral access in c-TACE,"technical success, patient comfort, complications",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
251,patients with hepatocellular carcinoma,cTACE with bevacizumab,cTACE with placebo,"radiologic progression, overall survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
252,patients with unresectable hepatocellular carcinoma,orantinib combined with cTACE,placebo combined with cTACE,overall survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
253,patients with hepatocellular carcinoma,TACE vs SBRT,not specified,treatment plan quality,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
254,patients with unresectable advanced hepatocellular carcinoma,nintedanib,sorafenib,"time-to-progression, overall survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
255,patients with hepatocellular carcinoma with PVTT,TACE with iodine-125 seed strand,conventional TACE,survival time,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
256,patients with small hepatocellular carcinoma,traditional herbal medicine,TACE,"recurrence-free survival, overall survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
257,patients with advanced hepatocellular carcinoma,ramucirumab,placebo,overall survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
258,patients with advanced hepatocellular carcinoma,urea-based cream,best supportive care,hand-foot skin reaction,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
259,patients with advanced hepatocellular carcinoma,radioembolisation with yttrium-90 microspheres,sorafenib,overall survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
260,patients with hepatocellular carcinoma,DEB-TACE,conventional TACE,"time-to-tumour progression, 2-year survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
261,patients with liver cancer,"sorafenib, TACE, sorafenib combined with TACE",TACE or sorafenib alone,"total effective rate, total survival",not specified,False,intervention is not immune checkpoint inhibitors
262,patients with hepatocellular carcinoma previously treated with sorafenib,pembrolizumab plus best supportive care,placebo plus best supportive care,health-related quality of life,randomized controlled trial,True,matches all PICOS criteria
263,patients with differentiated thyroid carcinoma,sorafenib,not specified,"progression-free survival, adverse events",phase III trial,False,population is not hepatocellular carcinoma
264,patients with radioiodine-refractory differentiated thyroid cancer,lenvatinib,placebo,tumor size change,not specified,False,population is not hepatocellular carcinoma
265,Japanese patients with MET-high hepatocellular carcinoma,tivantinib,placebo,"progression-free survival, overall survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
266,patients with hepatocellular carcinoma progressing during sorafenib treatment,regorafenib,placebo,"overall survival, time to progression",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
267,patients with large hepatocellular carcinoma,TACE with bicarbonate,TACE without bicarbonate,"viable tumor residues, objective response rate",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
268,patients with hepatocellular carcinoma,clinical decision support system,handbook only,"nursing outcomes, patient outcomes",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
269,patients with unresectable hepatocellular carcinoma,radioembolization with sorafenib,radioembolization alone,serum angiogenic markers,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
270,patients with advanced hepatocellular carcinoma,brivanib,placebo,overall survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
271,patients with hepatocellular carcinoma and portal vein tumor thrombus,3DCRT followed by TACE,TACE followed by 3DCRT,"efficacy, toxicity, survival rates",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
272,patients receiving lenvatinib,urine protein:creatinine ratio (UPCR),24-hour urine protein,proteinuria monitoring,phase 3 study,False,population and intervention do not match PICOS criteria
273,patients with advanced hepatocellular carcinoma,ADI-PEG 20,placebo,overall survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
274,patients with primary or metastatic liver cancer,transcutaneous electrical acupoint stimulation (TEAS),placebo-acupuncture,nausea and vomiting,randomized controlled trial,False,population and intervention do not match PICOS criteria
275,Japanese patients with advanced hepatocellular carcinoma,ramucirumab,placebo,overall survival,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
276,single-nodule small hepatocellular carcinoma patients,preoperative neutrophil-to-lymphocyte ratio (NLR),not specified,"time to recurrence, overall survival",retrospective study,False,study design and intervention do not match PICOS criteria
277,patients with advanced hepatocellular carcinoma,tivantinib,placebo,survival advantage,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
278,patients with advanced hepatocellular carcinoma,Pexa-Vec (JX-594),not specified,dose-finding,randomized trial,False,intervention and outcome do not match PICOS criteria
279,advanced hepatocellular carcinoma patients,sorafenib,not specified,"overall survival, progression-free survival",phase III study,False,intervention is not immune checkpoint inhibitors
280,patients with hepatocellular carcinoma,medical ozone oil,urea ointment,incidence and severity of hand-foot skin reaction,randomized controlled trial,False,"intervention is not immune checkpoint inhibitors, outcome is not survival or response rate"
